Le Lézard
Classified in: Health
Subjects: MAV, PSF, FVT, CFG

/R E P E A T -- Media Advisory - Inuit Tapiriit Kanatami and Indigenous Services Canada to Brief Media on the Tuberculosis Elimination Framework/


OTTAWA, Dec. 7, 2018 /CNW/ - Please be advised that officials from Inuit Tapiriit Kanatami and Indigenous Services Canada will provide a briefing on the newly ratified Inuit Tuberculosis Elimination Framework. This Framework will guide efforts to eliminate tuberculosis among Inuit living in Inuit Nunangat by 2030.

The briefing will include a background of the Framework's development, and provide an outline of activities undertaken to prevent and treat tuberculosis in Inuit Nunangat. Following the briefing, experts from both Inuit Tapiriit Kanatami and Indigenous Services Canada will answer questions from the media.

Dial-in info and relevant documents will be shared upon request by email at [email protected]. Please note that the documents will be provided under embargo on December 9.

Date: Monday, December 10, 2018

Time: 10:00 a.m. ? 11:30 a.m. (EST)

Follow us on Twitter:

Inuit Tapiriit Kanatami
(https://twitter.com/ITK_CanadaInuit) 

GovCan ? Indigenous
(https://twitter.com/GCIndigenous)

 

SOURCE Indigenous Services Canada


These press releases may also interest you

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...



News published on and distributed by: